Emodin inhibits HDAC6 mediated NLRP3 signaling and relieves chronic inflammatory pain in mice

Exp Ther Med. 2023 Dec 1;27(1):44. doi: 10.3892/etm.2023.12332. eCollection 2024 Jan.

Abstract

Chronic pain reduces the quality of life and ability to function of individuals suffering from it, making it a common public health problem. Neuroinflammation which is mediated by the Nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation in the spinal cord participates and modulates chronic pain. A chronic inflammatory pain mouse model was created in the current study by intraplantar injection of complete Freund's adjuvant (CFA) into C57BL/6J left foot of mice. Following CFA injection, the mice had enhanced pain sensitivities, decreased motor function, increased spinal inflammation and activated spinal astrocytes. Emodin (10 mg/kg) was administered intraperitoneally into the mice for 3 days. As a result, there were fewer spontaneous flinches, higher mechanical threshold values and greater latency to fall. Additionally, in the spinal cord, emodin administration reduced leukocyte infiltration level, downregulated protein level of IL-1β, lowered histone deacetylase (HDAC)6 and NLRP3 inflammasome activity and suppressed astrocytic activation. Emodin also binds to HDAC6 via four electrovalent bonds. In summary, emodin treatment blocked the HDAC6/NLRP3 inflammasome signaling, suppresses spinal inflammation and alleviates chronic inflammatory pain.

Keywords: Nod-like receptor family pyrin domain-containing 3 inflammasome; chronic inflammatory pain; emodin; histone deacetylase 6.

Grants and funding

Funding: The present study was funded by the Hubei University of Science and Technology Program (grant nos. BK202213, 2021WG06, 2022YKY02 and 2022YKY09), as well as the Research Project of the Hubei Provincial Department of Education (grant nos. ZY2023F109, B2022186 and B2022185).